Harrow Health(US:HROW)2025-03-28 15:39Financial Performance - Revenues for Q4 2024 reached $66.8 million, and for the full year 2024, revenues were $199.6 million[7] - GAAP net income for Q4 2024 was $6.8 million, while the GAAP net loss for the full year 2024 was $(17.5) million[7] - Core net income for Q4 2024 was $11.4 million, and the core net loss for the full year 2024 was $2.1 million[7] - Adjusted EBITDA was $22.5 million for Q4 2024 and $40.3 million for the full year 2024[7] - Gross margin was 79% for Q4 2024 and 75% for the full year 2024[7] - Core gross margin was 84% for Q4 2024 and 80% for the full year 2024[7] - Harrow projects consolidated revenues of $280 million for 2025[9] Product Performance - IHEEZO quarterly customer unit demand increased sequentially, reaching 49,130 units in Q4 2024[13] - VEVYE quarterly prescriptions also increased, reaching 63,925 in Q4 2024[16] ImprimisRx - ImprimisRx revenues were $83.499 million in 2024[24] Melt Pharmaceuticals - Harrow owns 46% equity ownership in Melt Pharmaceuticals[27] - Positive topline Phase 3 clinical data for MELT-300 was reported in Q4 2024[29]